On August 11, PhRMA submitted comments to the Office of the United States Trade Representative (USTR) containing recommendations on how to advance an inclusive and worker-centered trade agenda, objectives established by the Biden Administration. In addition to providing concrete and worker-centered recommendations, PhRMA’s comments demonstrate how USTR’s policies harm U.S. workers and fail to achieve the Administration’s own objectives.
The submission highlights five key areas:
1. The U.S. biopharmaceutical industry employs a highly diverse workforce and is a leading employer of female inventors. Women and racial minorities accounted for nearly 60% and 80%, respectively, of all U.S. biopharma manufacturing jobs created over the last 5 years.
2. The industry is a key driver of the U.S. economy, with direct output exceeding $700 billion annually. The industry supports nearly 4.5 million U.S. jobs and employs more manufacturers than each of the iron and steel, aerospace, petroleum and coal, and electric equipment and appliances industries.
3. The industry’s diverse U.S. workforce depends on robust international trade and investment policies. Due to longstanding U.S. trade policies that value innovation, protect intellectual property (IP) rights and champion open trade, the innovative biopharma industry exported $89 billion in medicines in 2022 and attracted $148 billion in foreign investment into the United States over the past five years.
4. The Administration’s trade policies harm America’s biopharmaceutical workers and fail to advance a more inclusive and worker-centered trade agenda. USTR has refused to negotiate new and meaningful trade agreements, prioritized unambitious economic dialogues like IPEF, supported foreign efforts to undermine American IP with the TRIPS waiver and failed to dismantle trade barriers at the World Trade Organization.
5. A more inclusive and worker-centered trade agenda must prioritize innovation, protect IP and champion open trade. This Administration’s misguided trade policies harm the very workers and communities that the Administration claims to want to help by depriving those workers of opportunities to compete in the global economy, reap the benefits of American innovation and labor without fear of foreign theft of American IP.
As the data in PhRMA’s comments demonstrate, the U.S. innovative biopharmaceutical industry provides significant opportunities for American workers engaged in research, invention and manufacturing to compete successfully in the global economy. Unfortunately, the Administration’s trade policy fails to promote — and often actively harms — this major U.S. industry, disadvantaging its hundreds of thousands of workers, their families and their communities. USTR should prioritize trade policies that support the large and diverse U.S. workforce engaged in the development and production of lifesaving medicines.
Go deeper by reading our comment letter to USTR and infographic.
Douglas Petersen
Douglas Petersen is PhRMA’s Vice President for international trade. Previously, he was international trade counsel for the U.S. Senate Committee on Finance, an international trade attorney with White & Case LLP and a trade policy analyst at the Cato Institute. He received a law degree from New York University, a graduate degree from the London School of Economics, and undergraduate degrees from the University of Utah.
Douglas Petersen
ICYMI: Pennsylvania shows what biopharmaceutical innovation can deliver
Staffing up: Building the future biopharma workforce to keep America in the lead
MFN price controls threaten American jobs and the U.S. economy
America Cures: Championing U.S. leadership in medical innovation
Middlemen mark up drug prices and keep discounts meant for you
Celebrating STEM Day: Investing in America’s innovators
Manufacturing U.S. jobs and breakthroughs
Historic biopharmaceutical investments: A prescription for America’s future
Tariffs on medicines would harm American competitiveness, industry and patients
Strong Trade Policies Protect American Workers and Biopharmaceutical Innovation
New research: Industry sponsored clinical trials contribute billions to state economies
USTR remembers—three years later—that it announced a trade initiative with Europe
PhRMA submission calls for USTR to correct course on trade policy, enforcement
Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers
No Region Left Behind: USTR expands its unambitious trade agenda to the western hemisphere
World Trade Week 2024: Time for a more ambitious U.S. trade agenda
Biopharmaceutical industry supports jobs and drives economic growth across the United States
Why won’t USTR strengthen medical supply chains with America’s allies?
PhRMA 2024 Special 301 submission: USTR needs to support American innovation, global access to medicines
Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation
PhRMA submission: USTR needs more ambition to combat unfair trade barriers
Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth
U.S. biopharmaceutical exports support jobs, innovation
Will the administration capitalize on the Indo-Pacific Economic Framework to drive medical innovation?
Biden administration should prioritize innovation in U.S.-Taiwan Initiative on 21st-Century Trade
PhRMA submission to USTR calls for urgent defense of American innovation abroad
Partnerships are driving global COVID-19 treatment access
The dangers of expanding the TRIPS waiver
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
The Senate’s latest price setting proposal will undermine U.S. economic growth
ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
Biden Administration details inadequate protection of American intellectual property and foreign barriers to innovation abroad
PhRMA encourages Biden administration to pursue ambitious Indo-Pacific Economic Framework
Biopharmaceutical industry drives economic growth in all 50 states
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
Strengthening the WTOs global trade and health agenda
PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
The Biden Administration allows politics to upend a pragmatic pandemic response
American leadership on innovation policy is essential to global health progress
Beyond output and employment: The impact of America’s biopharmaceutical industry
Preserving U.S. innovation worldwide is more important than ever
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
Manufacturing Day 2020: A closer look at the biopharmaceutical industry’s contributions
America’s global leadership in biopharmaceutical manufacturing
The continued imperative to protect U.S. innovation worldwide
New report: Biopharmaceutical industry supports over 4 million jobs and $1.1 trillion in U.S. economic output
Trump administration must defend and protect U.S. innovation
What you need to know about H.R. 3
New poll: 76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines
PhRMA submission to 2020 National Trade Estimate Report: Urgent action required to protect U.S. biopharmaceutical innovation
IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
What they are saying: Negative impact of Pelosi’s plan on biopharmaceutical innovation
Pelosi’s radical plan leaves lung cancer patients behind
Event tomorrow: Maintaining America’s leadership in access and innovation
Pelosi’s radical plan would leave Alzheimer’s patients behind
What they are saying: Broad opposition to Pelosi’s radical drug pricing plan
On Manufacturing Day, a closer look at the biopharmaceutical sector’s contributions
By the Numbers: Pelosi’s radical plan puts America’s economy and jobs at risk
Setting the record straight on international reference pricing
World Trade Month: How we can expand world-class pro-innovation standards
New Report: Advanced manufacturing powering innovative biopharmaceuticals
Clinical trials impact state economies
Special 301 submission calls for a level playing field for American innovators
Fact Check: Biologics, regulatory data protection and the United States-Mexico-Canada Agreement
Biopharmaceutical venture capital is spurring innovation and economic growth
PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation
PhRMA member companies R&D investments hit record high in 2017 - $71.4 billion
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
Researchers bring focus on science and medicine to California’s capital city
To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements
New Report: America's biopharmaceutical industry supports 4.7 million jobs
New PhRMA resources chock full of biopharma industry facts
Poll respondents appreciate economic benefits of innovation and call for more protections
New medicines are part of the solution to hold down future health care costs
As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority
Foreign government price setting by any name harms innovation and access to medicines
Compulsory licensing: A misused and abused international trade law
Government-imposed price controls threaten innovation and access
ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation
Illegal trade barriers discriminate against U.S. innovators
Trading fair means upholding the law: A focus on patents
Enforcing unmet trade obligations protects U.S. innovation
NAFTA tribunal fails to rule on Canada’s patent utility doctrine
PhRMA urges USTR to protect American innovators abroad
"The Biden Administration has failed to advance an inclusive, worker-centered trade agenda"
Economic Impact
Trade
The Biden Administration has failed to advance an inclusive, worker-centered trade agenda
"The Biden Administration has failed to advance an inclusive, worker-centered trade agenda"